Source-grounded facts extracted from ORAMED PHARMACEUTICALS INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ORAMED PHARMACEUTICALS INC. completed a disposition involving Lifeward Ltd. for Lifeward issuing to the Company a number of ordinary shares, no par value per share, of Lifeward, and pre-funded warrants to purchase the number of Lifeward Ord (closed 2026-03-25).
“On March 25, 2026, Lifeward completed its acquisition of Oratech in accordance with the terms of the Share Purchase Agreement.”
ORAMED PHARMACEUTICALS INC. entered into Warrant Agreement with Scilex Holding Company (effective 2026-02-19).
“On February 19, 2026, Oramed Pharmaceuticals Inc. (the “Company”) entered into a Warrant Agreement (the “Warrant Agreement”) with Scilex Holding Company (“Scilex”).”
ORAMED PHARMACEUTICALS INC. entered into Share Purchase Agreement with Lifeward Ltd. (effective 2026-01-12).
“On January 12, 2026, Oramed Pharmaceuticals Inc. (the “Company”) entered into that certain Share Purchase Agreement (“Share Purchase Agreement”), by and among the Company, Lifeward Ltd. (“Lifeward”) and Oratech Pharma, Inc., the Company’s wholly-owned subsidiary (“Oratech”).”
Avraham Gabay was appointed as Chief Financial Officer, Treasurer and Secretary at ORAMED PHARMACEUTICALS INC..
“On June 6, 2024, Oramed Pharmaceuticals Inc. (the “Company”) appointed Mr. Avraham Gabay to serve as the Chief Financial Officer, Treasurer and Secretary of the Company, effective as of June 18, 2024.”
David Silberman resigned as Chief Financial Officer, Treasurer and Secretary at ORAMED PHARMACEUTICALS INC..
“On May 10, 2024, David Silberman, the Chief Financial Officer, Treasurer and Secretary (the “CFO”) of Oramed Pharmaceuticals Inc. (the “Company”), resigned from his positions with the Company for personal reasons, effective as of July 12, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.